Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Vascular Diseases 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Hemorrhagic Disorders 1Hematologic Diseases 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

Dexamethasone 12Bortezomib 9Lenalidomide 6Cyclophosphamide 5isatuximab 3fludarabine 3daratumumab 3Granulocyte Colony-Stimulating Factor 3pomalidomide 2filanesib 2dacetuzumab 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Filgrastim 2Clinical Protocols 2Calcium Dobesilate 2Alemtuzumab 2plerixafor 1nirogacestat 1fludarabine phosphate 1ficlatuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tissue Banks 1Thalidomide 1Stem Cell Transplantation 1Ranitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × ficlatuzumab × Plasma cell × Clear all
NCT00725634 2014-01-27

P05538

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
41 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡